The global markets challenge the position of the pharmaceutical human businesses with different demands, like ways of pricing, patient orientation and ESG (environment, sustainability, and governance) to name a few. Some of these are kind of developments to which the industry has the competence to adapt easily, as history has witnessed.
What is new is the fact that the industry finds itself in an accumulation of characteristics acquired in its development since its origine. It has brought the industry in the current beneficial shape, its volume and routines of doing business. But that is up to now.